Author

Jon Earls

Observed names: Earls, Jon, J. Earls

Institution: Cofactor Genomics (United States)

Observed institution: Cofactor Genomics (United States)

OpenAlex ID: A5021783228

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2022 · Peter H. Goff, Laura Riolobos, et al. · Clinical Cancer Research · 47

T cell subtype profiling measures exhaustion and predicts anti-PD-1 response

2022 · Ian Schillebeeckx, Jon Earls, et al. · Scientific Reports · 20

Analytical Performance of an Immunoprofiling Assay Based on RNA Models

2020 · Ian Schillebeeckx, Jon R. Armstrong, et al. · Journal of Molecular Diagnostics · 15

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study

2024 · Kevin C Flanagan, Jon Earls, et al. · Journal for ImmunoTherapy of Cancer · 9

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma

2023 · Kevin C. Flanagan, Jon Earls, et al. · Journal of Cancer Research and Clinical Oncology · 8

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

2025 · Jeffrey Hiken, Jon Earls, et al. · BMC Cancer · 2

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

2024 · Zaker Rana, Sophia C. Kamran, et al. · European Urology Oncology · 2

Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT Study

2024 · Kevin C. Flanagan, Jon Earls, et al. · medRxiv · 1

Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study

2026 · Kevin C. Flanagan, Jon Earls, et al. · npj Precision Oncology

Predicting Anti-PD-1 Benefit in RM-HNSCC Patients with PD-L1 CPS 1-19: A Readout From The Multi-Center PREDAPT Trial

2026 · K. Price, K. Flanagan, et al. · International Journal of Radiation Oncology*Biology*Physics

Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

2024 · Jeffrey Hiken, Jon Earls, et al. · Research Square

Supplementary Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Supplementary Figure from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Supplementary Figure from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Supplementary Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Data from Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

2023 · Peter H. Goff, Laura Riolobos, et al.

Works count: 22

Citation count: 104

H-index: 5

I10-index: 3